Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. TheStreet lowered Accuray from a "c-" rating to a "d" rating in a report on Thursday, April 28th. B. Riley initiated coverage on shares of Accuray in a research note on Thursday, June 23rd. They issued a "buy" rating and a $7.50 price target for the company. BTIG Research lowered their price objective on shares of Accuray from $9.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday, June 24th. Finally, StockNews.com cut Accuray from a "buy" rating to a "hold" rating in a report on Tuesday. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.33.
Accuray Price Performance
Accuray stock traded up $0.10 during mid-day trading on Wednesday, hitting $2.92. The company's stock had a trading volume of 542,830 shares, compared to its average volume of 926,335. The stock has a market capitalization of $270.98 million, a P/E ratio of -47.17 and a beta of 1.82. Accuray has a twelve month low of $1.70 and a twelve month high of $5.93. The stock's fifty day moving average price is $2.11 and its two-hundred day moving average price is $2.74. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 3.36.
Accuray (NASDAQ:ARAY - Get Rating) last announced its earnings results on Wednesday, August 10th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. Accuray had a negative return on equity of 10.81% and a negative net margin of 1.24%. During the same quarter last year, the firm earned ($0.01) EPS. Research analysts forecast that Accuray will post 0.01 earnings per share for the current year.